Showing results (31-40 of 166) with videos related to
Sort By:
Pageof 17
Journal of Clinical Pharmacy and Therapeutics|May 7, 2011
A proposed mechanism for chemotherapy-related cognitive impairment ('chemo-fog')R B RaffaJournal of Clinical Pharmacy and Therapeutics|May 10, 2013
Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment)R B RaffaJournal of Clinical Pharmacy and Therapeutics|February 24, 2010
The M5 muscarinic receptor as possible target for treatment of drug abuseR B RaffaJournal of Clinical Pharmacy and Therapeutics|July 30, 2014
The clinical analgesic efficacy of buprenorphineR B Raffa, M Haidery, H-M Huang, et al.Neuroscience Letters|June 30, 1986
Evidence for a role of conditioning in the development of tolerance to morphine-induced inhibition of gastrointestinal transit in ratsR B Raffa, F PorrecaLife Sciences|January 1, 1989
Thermodynamic analysis of the drug-receptor interactionR B Raffa, F PorrecaNIDA Research Monograph|January 1, 1991
[D-Met2]-FMRFamide (DMFa): production of naloxone-sensitive antinociception in mouse tail-flick testR B Raffa, C D ConnellyLife Sciences|January 1, 1994
Opioid mu receptor subtypes (possibly mu 1 and mu 2) revealed by morphine-induced antinociception vs endothelin-1 in recombinant inbred CXBK miceR B Raffa, J J SchupskyPeptides|January 1, 1996
Could dual G-protein coupling explain [D-Met2]FMRFamide's mixed action in vivo?R B Raffa, D J StoneJournal of Neuroimmunology|May 1, 1989
Obligatory role of B cells and adherent accessory cells in the transfer of a defect in morphine-mediated antinociception in C57BL/6J-bg/bg (beige-J) miceE S Kimball, R B RaffaPageof 17